Garelius HKG

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Garelius

Contact Garelius, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Feb 01, 2025 |

By D'Aveni M, Koinig KA, Garelius HKG, van Marrewijk C

| aamds.org

Background: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive (RBCT).

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Garelius

Contact Garelius, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Overview

Use Cases

Capabilities

Industries

Library

Commmunity

Customers

Garelius HKG

Get in touch with Garelius

Actions

Is this you?

Articles

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Actions

Is this you?

Get in touch with Garelius